Company will accelerate Revita® weight maintenance clinical study REMAIN-1; open label data from REVEAL-1 cohort expected in Q4 2024 and mid-point data analysis for REMAIN-1 anticipated in Q2 2025
Company will accelerate Revita® weight maintenance clinical study REMAIN-1; open label data from REVEAL-1 cohort expected in Q4 2024 and mid-point data analysis for REMAIN-1 anticipated in Q2 2025
FRACTYL HEALTH INC
NASDAQ:GUTS (2/7/2025, 8:00:01 PM)
After market: 1.5107 +0 (+0.05%)1.51
-0.1 (-6.21%)
Discover the top movers in Friday's pre-market session and stay informed about market dynamics.